Outcomes in randomized controlled trials of therapeutic interventions for multiple myeloma: A systematic review

This publication has 48 references indexed in Scilit:

• SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis
  eClinicalMedicine, 2023
• Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review
  American Journal of Hematology, 2021
• Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials
  JAMA Network Open, 2020
• How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review
  Quality of Life Research, 2019
• Evaluation of spin in oncology clinical trials
  Critical Reviews in Oncology/Hematology, 2019
• Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
  Clinical Lymphoma Myeloma and Leukemia, 2019
• Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
  JAMA Internal Medicine, 2019
• Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
  Current Hematologic Malignancy Reports, 2019
• A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
  European Journal of Cancer, 2019
• Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
  American Journal of Hematology, 2016